CAR T-Cell Therapy
Phase 2 Study of the Oral Hypoxia-Inducible Factor 2a (HIF-2a) Inhibitor MK-6482 in Combination with Cabozantinib in Patients with Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
The Very Favorable Metastatic Renal Cell Carcinoma (mRCC) Risk Group: Data From the International Metastatic RCC Database Consortium (IMDC)
CAR T-cell and Transplant: Cellular Therapies for Malignant Disease
CD19-Targeted Chimeric Antigen Receptor (CAR)-Modified T Cell Immunotherapy For Adult B Cell Malignancies
CAR T Cell Therapy for Autoimmune Blistering Disease | Research at Penn
Chimeric Antigen Receptor T- Cells: Background, Toxicies, and Efficacy
Cancer
Cardiology
Gastroenterology
Neurology
OBGYN
Orthopedics
Pediatrics
Dental
Dermatology
Diabetes & Endocrinology
Infectious Diseases
Ophthalmology
Otolaryngology
Pulmonology
Surgery
Urology
person Sign In / Create Account
